Dr. Schroeder on Tolerability of Treatment For Myeloma

Video

In Partnership With:

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.

When patients are treated with regimens that include pomalidomide (Pomalyst), they are typically at risk of developing neutropenia. This often leads to dose reduction—whether it is combining pomalidomide with bortezomib (Velcade) or pomalidomide with daratumumab (Darzalex) and dexamethasone. In general, Schroeder notes, these doublet and triplet regimens are manageable and patients can get through them without any major issues.

Infusion reactions to daratumumab-based regimens are possible, but with split dosing this is particularly avoidable. Infusion time is also lessened in that setting with proper pre-dosing. Because of the lack of single-agent activity with elotuzumab (Empliciti), Schroeder adds, there is still ongoing work testing it in combination with other agents.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute